欢迎访问中国中西医结合杂志！

目的观察中医辨证分型治疗对帕金森病患者使用美多巴的减毒增效作用。方法共选择帕金森病患者101例进行前瞻性分层随机试验,其中强直少动型用帕病1号方加美多巴片(帕病1号组,22例)治疗,震颤型用帕病3号方加美多巴片(帕病3号组,30例)治疗,对照组采用中药协定方加美多巴片(49例)治疗。3组均以3个月为1个疗程。观察临床疗效及治疗前后帕金森病评定量表(UPDRS评分),并进行不良反应监测。结果治疗后,帕病3号组UPDRS评分各项积分和总分均有明显改善(P<0.01),帕病1号组、对照组各项积分明显改善(P<0.01),帕病1号组、帕病3号组的改善幅度优于对照组(P<0.01);帕病1号组、帕病3号组、对照组进步率分别为95.5%(21/22例)、100.0%(30/30例)和83.7%(45/49例),帕病1号组、帕病3号组优于对照组,差异有显著性(P<0.05)。帕病1号组治疗前后并发症积分差值与对照组比较,差异有显著性(P<0.05)。结论中医辨证分型治疗帕金森病能够改善症状、减少并发症,对美多巴有减毒增效的作用。

英文摘要:

Objective To observe the effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa in patients with Parkinson’s disease(PD). Methods The trial was conducted in 101 PD patients with a prospective stratified randomized and controlled method. They were assigned to group 1 in which the patients of rigidity were treated with Pabing Recipe 1 (PR1) plus Madopa tablets, group 2 with those of tremor given Pabing Recipe 3 (PR3) plus Madopa tablets, and group 3 given a fixed Chinese recipe plus Madopa tablets as the control. The treatment course for all the groups was 3 months. Clinical efficacy was evaluated with unified Parkinson’s disease rating scale (UPDRS) and the adverse reactions observed before and after treatment. Results After treatment, the 4 partial scores and the total score of UPDRS decreased significantly in group 2 (P<0. 01), and the former of them and the total score declined in group 1 and 3 (P<0. 01), the improvement was better in group 1 and 2 than that in group 3 (P<0. 01); the improvement rate in group 1 to 3 was 95.5%, 100.0% and 83.7%, respectively, which was significantly higher in group 1 and 2 than that in group 3 (P<0. 05). Conclusion TCM treatment according to syndrome differentiation could improve the clinical symptoms and reduce complications in PD patients, which could enhance curative effect and reduce side-effect of madopa.

View Full Text View/Add Comment Download reader